Physicians hesitant to switch patients from biologics to biosimilar drugs, report finds

Analyses have predicted that the use of biosimilar drugs could cut overall U.S. drug spending by more than $100 billion in the next five years, but many physicians are hesitant to switch patients from biologics to biosimilars, Kaiser Health News reported Sept. 23.